Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (3736)	10/6/1999 9:17:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 10280

This is kind of old news - basically Lehany was bringing her estimate of Xopenex sales into line with other analysts. I'm encouraged by the trend in Xopenex script numbers, which should also climb as asthma season approaches. There are also reports of a deal with Innovex (a QTRN division) to detail the drug, although there's been no official confirmation. Still no buzz on the asthma newsgroup about Xopenex - someone needs to learn a little guerilla marketing here - get a satisfied patient or two to post their experiences. Peter